Patents

TICEBA is exclusive licensee of the following patents:

USA

  • Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. „Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof.“ US Patent 6,846,883. January 25, 2005.
  • Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. „Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-2 and uses thereof.“ US Patent 7,465,554. December 16, 2008.
  • Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. „Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof.“ US Patent 8,076,091. December 13, 2011.
  • Frank MH; The Brigham and Women’s Hospital, Inc. „ABCB5 positive mesenchymal stem cells as immunmodulators.“ US Patent 8,455,245. June 4, 2013.

Europe

  • Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. „A gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof.“ European Patent EP1290028. 01. December 2010.

News
License

Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

Clinical Trial

Together with our subsidiary RHEACELL we are recruiting patients with the indication chronic venous ulcer (CVU) for the clinical trial in phase 1/2a. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.

Newsletter